The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Commercial SupportSM of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational program process—from development through implementation—to ensure independence of educational activities. IASLC policies are outlined below.
In compliance with ACCME Standards, each individual in a position to control the content of an educational activity must disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant” financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Individuals who refuse to disclose relevant financial relationships are not allowed to have control of, or responsibility for, the development, management, presentation or evaluation of CME activities. All disclosures are reviewed for potential conflicts, and appropriate steps for resolution are taken when needed. Additionally, individuals must agree to comply with specific rules (attestations) to ensure content is balanced and evidence-based, does not promote the business interests of a commercial entity, and conforms to the generally accepted standard of experimental design, data collection and analysis. Presenters are also required to clearly identify any non-FDA approved uses of products. IASLC also monitors presentations for quality and compliance through direct observation (IASLC staff and CME committee members), and through member feedback on evaluation surveys.
For the IASLC 2020 World Conference on Lung Cancer (WCLC 2020), disclosure information will be available for viewing as of January 27, 2021. Presenters are also required to include a disclosure slide listing all relevant financial relationships with commercial interests. CME related questions should be directed to IASLC at cme at iaslc.org.
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates this Other activity (blended live, simulive and on-demand materials) for a maximum of 66.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The IASLC WCLC 2020 is the world’s largest international gathering of clinicians, researchers, and scientists in the field of lung cancer and thoracic oncology. Bringing together lung cancer specialists from around the world and across disciplines, the meeting offers unique opportunities for collaboration, learning and sharing the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management. With 18 educational tracks and over 100 global experts as invited speakers, WCLC 2020 provides a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumor biomarkers, clinical trials, targeted therapies, liquid biopsy, screening, immunotherapy, tobacco control and patient advocacy even in a virtual environment. Sessions include plenaries with live Q&A, expert lectures, panel discussions, oral abstracts and posters.
The IASLC 2020 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.
At the conclusion of this activity, participants will be able to:
The official language of the IASLC 2020 World Conference on Lung Cancer is English.
The information presented at the IASLC 2020 World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Keep up to date with Conference News & Alerts.